Woonyoung Choi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/10886136/publications.pdf

Version: 2024-02-01

56 papers	7,530 citations	185998 28 h-index	189595 50 g-index
57 all docs	57 docs citations	57 times ranked	8494 citing authors

#	Article	IF	Citations
1	Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. European Urology, 2021, 79, 364-371.	0.9	41
2	Editorial: Recent Advances in Diagnosis and Management of Urothelial Carcinoma. Frontiers in Oncology, 2021, 11, 656974.	1.3	0
3	Evaluation of the Cancer of Bladder Risk Assessment (COBRA) Score in the Cancer Genome Atlas (TCGA) Bladder Cancer Cohort. Urology, 2021, 156, 104-109.	0.5	2
4	Expression Analysis of Same-Patient Metachronous and Synchronous Upper Tract and Bladder Urothelial Carcinoma. Journal of Urology, 2021, 206, 548-557.	0.2	9
5	Role of immunotherapy in localized muscle invasive urothelial cancer. Therapeutic Advances in Medical Oncology, 2021, 13, 17588359211045858.	1.4	4
6	A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. European Urology, 2020, 77, 420-433.	0.9	741
7	Adaptive Immune Resistance to Intravesical BCG in Nonâ€“Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials. Clinical Cancer Research, 2020, 26, 882-891.	3.2	98
8	Urothelial-to-Neural Plasticity Drives Progression to Small Cell Bladder Cancer. IScience, 2020, 23, 101201.	1.9	18
9	The Immunosuppressive Niche of Soft-Tissue Sarcomas is Sustained by Tumor-Associated Macrophages and Characterized by Intratumoral Tertiary Lymphoid Structures. Clinical Cancer Research, 2020, 26, 4018-4030.	3.2	44
10	Assessment of Luminal and Basal Phenotypes in Bladder Cancer. Scientific Reports, 2020, 10, 9743.	1.6	83
11	TCF21 Promotes Luminal-Like Differentiation and Suppresses Metastasis in Bladder Cancer. Molecular Cancer Research, 2020, 18, 811-821.	1.5	4
12	Reply To Kenneth B. Yatai, Mark J. Dunning, Dennis Wang. Consensus Genomic Subtypes of Muscle-invasive Bladder Cancer: A Step in the Right Direction but Still a Long Way To Go. Eur Urol 2020;77:434â€“5. European Urology, 2020, 77, 436-438.	0.9	1
13	Update on bladder cancer molecular subtypes. Translational Andrology and Urology, 2020, 9, 2881-2889.	0.6	28
14	Tumor heterogeneity in muscle-invasive bladder cancer. Translational Andrology and Urology, 2020, 9, 2866-2880.	0.6	11
15	Whole-Organ Genomic Characterization of Mucosal Field Effects Initiating Bladder Carcinogenesis. Cell Reports, 2019, 26, 2241-2256.e4.	2.9	31
16	ERCC2 Mutation: The Marker for Chemosensitivity in Primary and Secondary Muscle-invasive Bladder Cancers. European Urology, 2019, 75, 240-241.	0.9	2
17	Subtyping Bladder Cancers: Biology vs Bioinformatics. Journal of the National Cancer Institute, 2018, 110, 439-440.	3.0	4
18	Apoptosis: Signaling Pathways in Pancreatic Cancer Pathogenesis. , 2018, , 369-382.		0

#	Article	IF	Citations
19	Reply to Joshua A. Linscott, Angela B. Smith, and Jesse D. Sammon's Letter to the Editor re: Woonyoung Choi, Andrea Ochoa, David J. McConkey, et al. Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset. Eur Urol 2017;72:354â€“65. European Urology, 2018, 73, e104-e105.	0.9	1
20	Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-Invasive Bladder Cancer: Results of a Phase 2 Trial. European Urology Oncology, 2018, 1, 54-60.	2.6	26
21	Molecular Subtypes of Bladder Cancer. Current Oncology Reports, 2018, 20, 77.	1.8	111
22	A new 50-gene molecular subtype classifier: An evaluation of subtype stability and association with response to neoadjuvant chemotherapy in muscle-invasive bladder cancer.. Journal of Clinical Oncology, 2018, 36, 519-519.	0.8	4
23	Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy. European Urology, 2017, 72, 544-554.	0.9	638
24	Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset. European Urology, 2017, 72, 354-365.	0.9	195
25	Employing an orthotopic model to study the role of epithelial-mesenchymal transition in bladder cancer metastasis. Oncotarget, 2017, 8, 34205-34222.	0.8	13
26	Autophagy is required for crizotinib-induced apoptosis in MET-amplified gastric cancer cells. Oncotarget, 2017, 8, 51675-51687.	0.8	8
27	Apoptosis: Signaling Pathways in Pancreatic Cancer Pathogenesis. , 2017, , 1-14.		0
28	Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer. European Urology, 2016, 70, 611-620.	0.9	120
29	Intrinsic subtypes and bladder cancer metastasis. Asian Journal of Urology, 2016, 3, 260-267.	0.5	31
30	Bladder cancer. Lancet, The, 2016, 388, 2796-2810.	6.3	1,031
31	A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naÃ¯ve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer. European Urology, 2016, 69, 855-862.	0.9	228
32	New discoveries in the molecular landscape of bladder cancer. F1000Research, 2016, 5, 2875.	0.8	5
33	Specific micro-RNA expression patterns distinguish the basal and luminal subtypes of muscle-invasive bladder cancer. Oncotarget, 2016, 7, 80164-80174.	0.8	40
34	Genetic subtypes of invasive bladder cancer. Current Opinion in Urology, 2015, 25, 449-458.	0.9	35
35	Reply to Mattias Aine, Fredrik Liedberg, Gottfrid SjÃ¶dahl, and Mattias HÃ¶glund's Letter to the Editor re: David J. McConkey, Woonyoung Choi, Colin P.N. Dinney. New Insights into Subtypes of Invasive Bladder Cancer: Considerations of the Clinician. Eur Urol 2014;66:609â€“10. European Urology, 2015, 67, e76-e78.	0.9	3
36	Therapeutic Opportunities in the Intrinsic Subtypes of Muscle-Invasive Bladder Cancer. Hematology/Oncology Clinics of North America, 2015, 29, 377-394.	0.9	57

#	Article	IF	Citations
37	Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy. Cancer Cell, 2014, 25, 152-165.	7.7	1,358
38	Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer. Nature Reviews Urology, 2014, 11, 400-410.	1.9	267
39	New Insights into Subtypes of Invasive Bladder Cancer: Considerations of the Clinician. European Urology, 2014, 66, 609-610.	0.9	55
40	A Smac mimetic augments the response of urothelial cancer cells to gemcitabine and cisplatin. Cancer Biology and Therapy, 2013, 14, 812-822.	1.5	18
41	The p63 Protein Isoform Î”Np63Î± Inhibits Epithelial-Mesenchymal Transition in Human Bladder Cancer Cells. Journal of Biological Chemistry, 2013, 288, 3275-3288.	1.6	116
42	Fibroblast Growth Factor Receptors-1 and -3 Play Distinct Roles in the Regulation of Bladder Cancer Growth and Metastasis: Implications for Therapeutic Targeting. PLoS ONE, 2013, 8, e57284.	1.1	68
43	Inhibition of Inducible Heat Shock Protein-70 (Hsp72) Enhances Bortezomib-Induced Cell Death in Human Bladder Cancer Cells. PLoS ONE, 2013, 8, e69509.	1.1	35
44	p63 expression correlates with sensitivity to the Eg5 inhibitor AZD4877 in bladder cancer cells. Cancer Biology and Therapy, 2012, 13, 477-486.	1.5	18
45	p63 Expression Defines a Lethal Subset of Muscle-Invasive Bladder Cancers. PLoS ONE, 2012, 7, e30206.	1.1	71
46	Molecular Characterization of Pancreatic Cancer Cell Lines. , 2010, , 457-469.		3
47	Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progression. Urologic Oncology: Seminars and Original Investigations, 2010, 28, 429-440.	0.8	188
48	Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer. Cancer Research, 2009, 69, 5820-5828.	0.4	771
49	Delta-Crystallin Enhancer Binding Factor 1 Controls the Epithelial to Mesenchymal Transition Phenotype and Resistance to the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Human Head and Neck Squamous Cell Carcinoma Lines. Clinical Cancer Research, 2009, 15, 532-542.	3.2	76
50	Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. Cancer and Metastasis Reviews, 2009, 28, 335-344.	2.7	324
51	miR-200 Expression Regulates Epithelial-to-Mesenchymal Transition in Bladder Cancer Cells and Reverses Resistance to Epidermal Growth Factor Receptor Therapy. Clinical Cancer Research, 2009, 15, 5060-5072.	3.2	386
52	Inactivation of IÎºB contributes to transcriptional activation of spermidine/spermine N (1)-acetyltransferase. Molecular Carcinogenesis, 2006, 45, 685-693.	1.3	14
53	Transcriptional activation of the carboxylesterase 2 gene by the p53 pathway. Cancer Biology and Therapy, 2006, 5, 1450-1456.	1.5	20
54	Combination of 5-Fluorouracil and N1,N11-Diethylnorspermine Markedly Activates Spermidine/Spermine N1-Acetyltransferase Expression, Depletes Polyamines, and Synergistically Induces Apoptosis in Colon Carcinoma Cells. Journal of Biological Chemistry, 2005, 280, 3295-3304.	1.6	48

#	Article	IF	Citations
55	Understanding Cancer through Proteomics. Technology in Cancer Research and Treatment, 2002, 1, 221-230.	0.8	0
56	A Consensus Molecular Classification of Muscle-Invasive Bladder Cancer. SSRN Electronic Journal, 0, , .	0.4	9